Treatment of systemic lupus erythematosus with the T-cell immunopotentiator levamisole: a follow-up report of 16 patients under treatment for a minimum period of four months.

Treatment of 16 SLE patients with levamisole resulted in significant reduction of a variety of clinical parameters of the disease. Clinical improvement was both subjective and objective. Thus, levamisole may represent a possible alternative or adjunctive approach to SLE therapy. Although proper assessment of its actual quantitative importance in the treatment of Lupus must await large scale studies under double-blind conditions, nevertheless, these preliminary results are very encouraging.